Sign up Australia
Proactive Investors - Run By Investors For Investors

Pharmaxis has key drivers in place for short and long term value creation

Pharmaxis Ltd (ASX:PXS) chief executive Gary Phillips speaks to Proactive Investors about the pharmaceutical research company’s business model and value drivers, and provides some context about the sector, which is seeing a lot of headline-grabbing merger and acquisition activity.

"I think there's three things about our company that make us a little bit different from some of our peer group. I think the number one is that we have cash... secondly, the team that we've grown... and lastly,  I think, our portfolio... Pharmaxis isn't a company where we've just got one program; an investment in us isn't like putting money on black or red on a roulette table. We understand that early biotech companies [carry] a fair amount of risk and some programs may fall over, but we have a portfolio of drugs on the market, drugs that are already partnered, and drugs that are still in development," says Phillips.

Pharmaxis is in talks for a partnership deal on its LOXL2 anti‐fibrotic program, with hopes of announcing a partner in the second half of this year. Trial results from the Boehringer Ingelheim partnered program, which will potentially demonstrate proof of concept in patients for two indications, are expected out in the first half of next year.

 
Meet Bluerock Diamonds Plc, Rambler Metals and Mining PLC, Touchstone Exploration Inc and Stratex International plc at our event, London , 19 June 2018. Register here »
View full PXS profile View Profile

Pharmaxis Ltd Timeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use